Michael Forbes, CEO of Adastra, reported in his Preliminary press launch: “Harm reduction is often a critically critical and mainstream subject, and we've been keeping within the forefront of drug rules across the board.”Could offer substandard and falsified medications produced or distributed underneath unregulated and likely unsafe methods, o